General Information of Drug (ID: DMRH740)

Drug Name
CS-8080 Drug Info
Synonyms Liver X receptor modulator (artherosclerosis), Daiichi Sankyo Inc; LXR modulator (anti-arteriosclerotic), Daiichi Sankyo Inc
Indication
Disease Entry ICD 11 Status REF
Arteriosclerosis BD40 Phase 1 [1]
Cross-matching ID
PubChem CID
16212738
ChEBI ID
CHEBI:52027
CAS Number
CAS 127274-91-3
TTD Drug ID
DMRH740

Molecule-Related Drug Atlas

Molecule-Related Drug Atlas
Molecule Type:
DTT
Drug Status:
Clinical Trial Drug(s)
Investigative Drug(s)
Drug Name Drug ID Indication ICD 11 Highest Status REF
ALX-101 DMCAFXM Atopic dermatitis EA80 Phase 2 [3]
RGX-104 DM5AIKR Non-small-cell lung cancer 2C25.Y Phase 1/2 [4]
BMS-779788 DMKR8S1 Arteriosclerosis BD40 Phase 1 [2]
BMS-852927 DMZS1D2 Arteriosclerosis BD40 Phase 1 [2]
XL-041 DMYSQHT Arteriosclerosis BD40 Phase 1 [5]
XL652/XL014 DM89NML Cardiovascular disease BA00-BE2Z Phase 1 [6]
LXR 623 DM3OP41 Arteriosclerosis BD40 Phase 1 [2]
T0901317 DMZQVDI Discovery agent N.A. Investigative [7]
⏷ Show the Full List of 8 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Oxysterols receptor LXR (NR1H) TTM1EQF NOUNIPROTAC Modulator [2]

References

1 ClinicalTrials.gov (NCT00796575) Effects of Multiple Doses of CS-8080 in Healthy Volunteers. U.S. National Institutes of Health.
2 Liver X receptors in lipid metabolism: opportunities for drug discovery. Nat Rev Drug Discov. 2014 Jun;13(6):433-44.
3 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
4 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
5 Emerging small molecule drugs. Handb Exp Pharmacol. 2015;224:617-30.
6 Clinical pipeline report, company report or official report of Exelixis (2011).
7 The LXR ligand T0901317 induces severe lipogenesis in the db/db diabetic mouse. J Lipid Res. 2003 Nov;44(11):2039-48.